ArticleHuman vaccines & immunotherapeutics2025
Analysis of the economically justifiable price of nirsevimab to prevent respiratory syncytial virus infection in Korea.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current standard-of-care prophylaxis for respiratory syncytial virus (RSV) is primarily administered to high-risk infant populations. We conducted a cost-effectiveness analysis to determine the economically justifiable price of nirsevimab compared with the standard of care in preventing medically attended RSV-associated lower respiratory tract infections from all infants and palivizumab-eligible children <2 years in South Korea. A month-age-specific static decision-tree model was used from a societal perspective, with a primary time horizon of one RSV season and an extended time horizon of three years. The model compared nirsevimab with standard of care prevention, which included palivizumab for eligible infants and children under two during the RSV season. The outcome measure was an incremental cost-effectiveness ratio (ICER) to suggest economically justifiable prices. The maximum economically justifiable price of nirsevimab was $527 at a 1 gross domestic product (GDP) per capita willingness-to-pay (WTP) threshold and $607 at a 1.5 GDP per capita WTP threshold per quality-adjusted life year (QALY) gain. The ICER was $33,071 per QALY at the price of $527 and $49,769 per QALY at $607 for the total population. Sensitivity analyses identified RSV epidemiology, nirsevimab effectiveness, and price as the key drivers of ICER variations. Probabilistic sensitivity analyses showed that nirsevimab was cost-effective at $527 in 55% of the simulations at the 1 GDP threshold and 54% at the 1.5 GDP threshold. Nirsevimab is estimated to be a cost-effective intervention for preventing RSV-associated lower respiratory tract infections within a universal immunization program for all infants and palivizumab-eligible children <2 years in South Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.